Citations 1
A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum-resistant ovarian cancer (OC).
Weekes, Colin D. , Lamberts, Laetitia E., Voortman, Johannes, Yue, Huibin, Scales, Suzie J. , Samineni, Divya , Wood, Katie, Brunstein, Flávia, Maslyar, Daniel, Kim, George P., Borad, Mitesh J. , McWilliams, Robert R. , Diamond, Jennifer R. , Vries, Elisabeth G.E. de , Verheul, Henk M.W. , Lieu, Christopher H. , Wang, Yulei
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 2529-2529
